Sign in Subscribe
Drugs

Recent Research on Prostate Cancer Highlights Novel Targets and Therapeutic Strategies

Strategic Insights

— 1 min read

Recent studies from the United States and the People's Republic of China have shed light on the complex molecular mechanisms underlying prostate cancer progression and metastasis. Three research studies have identified novel targets and therapeutic strategies that may offer new hopes for the treatment of this aggressive and often lethal disease.

Key Takeaways:

  • Study 1: Gene expression profiling of prostate cancer cells revealed a set of 95 differentially regulated genes associated with p53 gain-of-function mutant alleles, providing insight into mechanisms underlying androgen independence. (Tepper et al., 2005)
  • Study 2: Aberrant expression of Delta Np73 was detected in benign and malignant tumors of the prostate, with a significant increase of Delta Np73 in carcinomas and benign prostate hyperplasia tissues. (Guan et al., 2005)
  • Study 3: The novel radiolabeled-antibody conjugate [[superscript]90Y]-CHX-A"-DTPA-19G9 inhibits tumor growth, targeting the mindin/RG-1 protein expressed selectively in prostate tissues. (Parry et al., 2005)

Statistics:

  • 95 differentially regulated genes identified in study 1, with 50 genes induced and 45 genes repressed by p53 gain-of-function mutant alleles.
  • 20 out of 33 carcinomas and 17 out of 24 benign prostate hyperplasia tissues showed significant increase of Delta Np73 expression in study 2.
  • A dose-finding study identified a nontoxic therapeutic dose of [[superscript]90Y]-CHX-A"-DTPA-19G9 to be similar to 75 mcCi in study 3.
  • Significant antitumor effects were seen with a single administration of radiolabeled antibody to animals bearing 200 to 400 mm[superscript]3 tumors in study 3.

Sources:

  • Tepper, C. G., et al. (2005). Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate, 65(4), 375-389.
  • Guan, M., et al. (2005). Aberrant expression of Delta Np73 in benign and malignant tumours of the prostate: correlation with Gleason score. Journal of Clinical Pathology, 58(11), 1175-1179.
  • Parry, R., et al. (2005). Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Research, 65(18), 8397-8405.

Read more